Renal cell carcinoma, VHL-associated

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Page editor Section editor
Teja Ganta, MD
Icahn School of Medicine at Mount Sinai
New York, NY, USA

Ali Raza Khaki, MD
Stanford University
Palo Alto, CA, USA


Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the main RCC page for other regimens.

1 regimens on this page
1 variants on this page


Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.


All lines of therapy

Belzutifan monotherapy


Study Dates of enrollment Evidence
Jonasch et al. 2021 (MK-6482-004) 2018-05-31 to 2019-03-29 Phase 2 (RT)

Targeted therapy

Continued indefinitely


  1. MK-6482-004: Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. link to original article contains dosing details in manuscript link to PMC article PubMed NCT03401788